The effects of iron injection on blood doping biomarkers in dried blood spots.


Journal

Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449

Informations de publication

Date de publication:
Apr 2023
Historique:
revised: 07 11 2022
received: 01 09 2022
accepted: 08 11 2022
medline: 4 4 2023
pubmed: 11 11 2022
entrez: 10 11 2022
Statut: ppublish

Résumé

Iron supplementation is not considered as a doping method; however, it can affect the levels of several biomarkers of the hematologic module of the athlete biological passport (ABP), such as the reticulocyte percentage (%RET) and hemoglobin (HGB) level. Thus, iron injection could be a confounding factor in antidoping analyses. Previous studies have suggested that the HGB level and the expression levels of reticulocyte-related-mRNAs, such as 5'-aminolevulinate synthase 2 (ALAS2) and carbonic anhydrase 1 (CA1), could be promising biomarkers for the ABP and detectable in dried blood spots (DBSs). Therefore, in this study, we examined the impact of iron injection on the levels of these potential biomarkers in DBSs. Reticulocyte-related-mRNAs analyses were performed by RT-qPCR. Ferritin level in DBS was measured with enzyme-linked immunosorbent assay (ELISA) method. Notably, there were no significant effects of iron supplementation on the levels of ALAS2 and CA1 mRNAs but by contrast, the %RET and immature reticulocyte fraction (IRF) measured in whole blood increased significantly following iron injection. As expected, iron supplementation increased the ferritin level significantly in both serum and DBS samples. In conclusion, these findings reinforce the specificity of reticulocyte-related mRNAs in DBSs as biomarkers of blood doping to target in antidoping analyses.

Identifiants

pubmed: 36354188
doi: 10.1002/dta.3407
doi:

Substances chimiques

Iron E1UOL152H7
Biomarkers 0
Ferritins 9007-73-2
Hemoglobins 0
ALAS2 protein, human EC 2.3.1.37
5-Aminolevulinate Synthetase EC 2.3.1.37

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

444-448

Subventions

Organisme : Partnership for Clean Competition
ID : # 0000000167

Informations de copyright

© 2022 John Wiley & Sons Ltd.

Références

Schumacher YO, Saugy M, Pottgiesser T, Robinson N. Detection of EPO doping and blood doping: the haematological module of the athlete biological passport: the haematological module of the athlete biological passport. Drug Test Anal. 2012;4(11):846-853. doi:10.1002/dta.406
World Anti-Doping Agency. WADA Technical Document - TD2021Bar; 2021.
Bonne TC, Lundby C, Lundby AK, Sander M, Bejder J, Nordsborg NB. Altitude training causes haematological fluctuations with relevance for the athlete biological passport: altitude training and the athlete biological passport. Drug Test Anal. 2015;7(8):655-662. doi:10.1002/dta.1757
Spodaryk K. Haematological and iron-related parameters of male endurance and strength trained athletes. Eur J Appl Physiol. 1993;67(1):66-70. doi:10.1007/BF00377707
Loria F, Cox HD, Voss SC, et al. The use of RNA-based 5′-aminolevulinate synthase 2 biomarkers in dried blood spots to detect recombinant human erythropoietin microdoses. Drug Test Anal. 2022;14(5):826-832.
Salamin O, Gottardo E, Schobinger C, et al. Detection of stimulated erythropoiesis by the RNA-based 5’-aminolevulinate synthase 2 biomarker in dried blood spot samples. Clin Chem. 2019;65(12):1563-1571. doi:10.1373/clinchem.2019.306829
Tuck MK, Chan DW, Chia D, et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res. 2009;8(1):113-117. doi:10.1021/pr800545q
Sharma A, Jaiswal S, Shukla M, Lal J. Dried blood spots: concepts, present status, and future perspectives in bioanalysis: an overview on dried blood spots. Drug Test Anal. 2014;6(5):399-414.
Cox HD, Miller GD, Lai A, Cushman D, Eichner D. Detection of autologous blood transfusions using a novel dried blood spot method. Drug Test Anal. 2017;9(11-12):1713-1720. doi:10.1002/dta.2323
Reverter-Branchat G, Ventura R, Ezzel Din M, Mateus J, Pedro C, Segura J. Detection of erythropoiesis-stimulating agents in a single dried blood spot. Drug Test Anal. 2018;10(10):1496-1507. doi:10.1002/dta.2418
Loria F, Stutz AP, Rocca A, et al. Monitoring of hemoglobin and erythropoiesis-related mRNA with dried blood spots in athletes and patients. Bioanalysis. 2022;14(5):241-251. doi:10.4155/bio-2021-0252
Ramirez Cuevas K, Schobinger C, Gottardo E, et al. Erythroferrone as a sensitive biomarker to detect stimulation of erythropoiesis. Drug Test Anal. 2020;12(2):261-267. doi:10.1002/dta.2720
Rocca A, Martin L, Kuuranne T, Ericsson M, Marchand A, Leuenberger N. A fast screening method for the detection of CERA in dried blood spots. Drug Test Anal. 2022;14(5):820-825.
Oshiro I, Takenaka T, Maeda J. New method for hemoglobin determination by using sodium lauryl sulfate (SLS). Clin Biochem. 1982;15(2):83-88. doi:10.1016/S0009-9120(82)91069-4
Loria F, Manfredi M, Reverter-Branchat G, Segura J, Kuuranne T, Leuenberger N. Automation of RNA-based biomarker extraction from dried blood spots for the detection of blood doping. Bioanalysis. 2020;12(11):729-736. doi:10.4155/bio-2020-0041
Salamin O, Mignot J, Kuuranne T, Saugy M, Leuenberger N. Transcriptomic biomarkers of altered erythropoiesis to detect autologous blood transfusion. Drug Test Anal. 2018;10(3):604-608. doi:10.1002/dta.2240
Favrat B, Balck K, Breymann C, et al. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women-PREFER a randomized, placebo-controlled study. PLoS ONE. 2014;9(4):e94217. doi:10.1371/journal.pone.0094217
Cook JD, Flowers CH, Skikne BS. An assessment of dried blood-spot technology for identifying iron deficiency. Blood. 1998;92(5):1807-1813. doi:10.1182/blood.V92.5.1807

Auteurs

Francesco Loria (F)

Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Lausanne and Geneva, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Estelle Maret (E)

Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Lausanne and Geneva, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Céline Schobinger (C)

Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Lausanne and Geneva, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Tiia Kuuranne (T)

Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Lausanne and Geneva, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Silke Grabherr (S)

University Center of Legal Medicine, Lausanne and Geneva, University Hospitals of Lausanne and Geneva, University of Lausanne and University of Geneva, Lausanne, Switzerland.

Nicolas Leuenberger (N)

Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Lausanne and Geneva, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH